Do you want to read an article? Please log in or register.
Epidemiology and treatment of Adamantiades-Behçet's disease in Germany: A healthcare claims database study
Further Publications Immunology
Indications
Related content
Further Publications Immunology
Safety and efficacy of TNF inhibitors in patients with Behçet's disease: Retrospective study from eastern Turkey
Clin Immunol
Bektaş M, Özer MD, Oğuz E
doi: 10.1016/j.clim.2024.110239
Further Publications Immunology
Patients' recollection about the onset of Sjögren's disease - a mixed methods study on the patients' perspective
Arthritis Res Ther
Lackner A, Dreo B, Hermann J, Zenz S, Fessler J, Thiel J, Stradner MH
doi: 10.1186/s13075-024-03404-8
Juvenile Idiopathic Arthritis
Systemic juvenile idiopathic arthritis and adult-onset Still's disease are the same disease: evidence from systematic reviews and meta-analyses informing the 2023 EULAR/PReS recommendations for the diagnosis and management of Still's disease
Ann Rheum Dis
De Matteis A, Bindoli S, De Benedetti F, Carmona L, Fautrel B, Mitrovic S
doi: 10.1136/ard-2024-225853
Further Publications Rheumatology
Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial
Ann Rheum Dis
Talarico R, Italiano N, Emmi G, Piga M, Cantarini L, Mattioli I, Floris A, Gentileschi S, Di Cianni F, Urban ML, Chiara E, Marinello D, Del Bianco A, Figus M, Posarelli C, Fabiani C, Vagnani S, Andreozzi G, Lorenzoni V, Turchetti G, Cauli A, Emmi L, Salvarani C, Della Casa Alberighi O, Bombardieri S, Mosca M
doi: 10.1136/ard-2024-226113
Further Publications Rheumatology
The clinical assessment of lung involvement in patients with Still's disease, results from the multicentre international AIDA Network Still's Disease Registry
Rheumatology (Oxford)
Ruscitti P, Vitale A, Di Cola I, Caggiano V, Palumbo P, Di Cesare E, Hinojosa-Azaola A, Torres-Ruiz J, Guaracha-Basañez GA, Martín-Nares E, Lopalco G, Morrone M, Iannone F, Giardini HAM, Cordeiro RA, de Brito Antonelli IP, Berardicurti O, Navarini L, Ciccia F, Visconti MC, Iacono D, Direskeneli H, Erten S, Yao H, Thabet M, Tharwat S, Ragab G, Gómez-Caverzaschi V, Sfikakis PP, Fotis L, La Torre F, Maier A, Karamanakos A, Almaghlouth IA, Frassi M, Tufan A, Govoni M, Sota J, Simonini G, Emmi G, Li Gobbi F, Parronchi P, Costi S, Sarzi-Puttini P, Opris-Belinski D, Sfriso P, Tarsia M, Maggio MC, Monti S, Gündüz ÖS, Rigante D, Bartoloni E, Verrecchia E, Iagnocco A, Viapiana O, Bargagli E, Batu ED, Sebastiani GD, Del Giudice E, Conti G, Breda L, Gidaro A, Gicchino MF, Gaggiano C, Brucato AL, Triggianese P, Makowska J, Carubbi F, Farina N, Guggino G, De Paulis A, Mazzei MA, Di Meglio N, Lo Gullo A, Conforti A, Ogunjimi B, Calabrese L, Rubegni P, Giardina A, Wiesik-Szewczyk E, Balistreri A, Fabiani C, Frediani B, Dagna L, Giacomelli R, Cantarini L
doi: 10.1093/rheumatology/keaf021
Further Publications Immunology
Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease
Ann Rheum Dis
Bindoli S, De Matteis A, Mitrovic S, Fautrel B, Carmona L, De Benedetti F
doi: 10.1136/ard-2024-225854
Autoimmune Disease
The evaluation of myocarditis in patients with Still's disease; clinical findings from the multicentre international AIDA Network Still's Disease Registry
J Rheumatol
Ruscitti P, Di Cola I, Vitale A, Caggiano V, Palumbo P, Di Cesare E, Torres-Ruiz J, Guaracha-Basañez GA, Martín-Nares E, Ciccia F, Iacono D, Riccio F, Maggio MC, Tharwat S, Hashad S, Rigante D, Ortolan A, Giardini HAM, Parente de Brito Antonelli I, Cordeiro RA, Giacomelli R, Navarini L, Berardicurti O, Conforti A, Opris-Belinski D, Sota J, Gaggiano C, Lopalco G, Iannone F, La Torre F, Mastrorilli V, Govoni M, Ruffilli F, Emmi G, Biancalana E, Sfikakis PP, Tektonidou M, Hernández-Rodríguez J, Gómez-Caverzaschi V, Gündüz ÖS, Conti G, Patroniti S, Gidaro A, Bartoli A, Olivieri AN, Gicchino MF, Brucato AL, Dagna L, Tomelleri A, Campochiaro C, De Paulis A, Mormile I, Della Casa F, Direskeneli H, Alibaz-Oner F, Karamanakos A, Dimouli A, Ragab G, Mahmoud Ahmed AA, Tufan A, Kucuk H, Kardas R, Batu ED, Ozen S, Wiesik-Szewczyk E, Hinojosa-Azaola A, Balistreri A, Fabiani C, Frediani B, Cantarini L
doi: 10.3899/jrheum.2024-0683
Further Publications Immunology
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
Lancet
Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM, Crandall W, Durand F, Hon E, Lin Z, Lopes MU, Morris N, Protic M, Carlier H, Sands BE, VIVID Study Group
doi: 10.1016/S0140-6736(24)01762-8
Autoimmune Disease
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study
Lancet
Fisher BA, Mariette X, Papas A, Grader-Beck T, Bootsma H, Ng WF, van Daele PLA, Finzel S, Noaiseh G, Elgueta S, Hermann J, McCoy SS, Akpek E, Bookman A, Sopala M, Montecchi-Palmer M, Luo WL, Scheurer C, Hueber W, TWINSS study group
doi: 10.1016/S0140-6736(24)01211-X